Tower Research Capital (TRC)’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.7K | Buy |
1,797
+664
| +59% | +$2.54K | ﹤0.01% | 4100 |
|
|
2025
Q4 | $5.48K | Buy |
+1,133
| New | +$4.74K | ﹤0.01% | 4118 |
|
|
2023
Q4 | – | Sell |
-111
| Closed | -$175 | – | 5944 |
|
|
2023
Q3 | $175 | Buy |
111
+66
| +147% | +$129 | ﹤0.01% | 5672 |
|
|
2023
Q2 | $89 | Buy |
+45
| New | +$86 | ﹤0.01% | 5831 |
|
|
2023
Q1 | – | Sell |
-26,362
| Closed | -$56K | – | 5856 |
|
|
2022
Q4 | $56K | Buy |
26,362
+19,300
| +273% | +$43.7K | ﹤0.01% | 2266 |
|
|
2022
Q3 | $16K | Buy |
7,062
+699
| +11% | +$2.12K | ﹤0.01% | 4112 |
|
|
2022
Q2 | $18K | Sell |
6,363
-1,886
| -23% | -$6.64K | ﹤0.01% | 3890 |
|
|
2022
Q1 | $37K | Buy |
8,249
+7,181
| +672% | +$39.6K | ﹤0.01% | 2957 |
|
|
2021
Q4 | $9K | Sell |
1,068
-941
| -47% | -$9.25K | ﹤0.01% | 4680 |
|
|
2021
Q3 | $25K | Sell |
2,009
-6,400
| -76% | -$88.6K | ﹤0.01% | 3513 |
|
|
2021
Q2 | $130K | Sell |
8,409
-324
| -4% | -$5.45K | ﹤0.01% | 2210 |
|
|
2021
Q1 | $176K | Buy |
8,733
+8,717
| +54,481% | +$216K | ﹤0.01% | 2121 |
|
|
2020
Q4 | $0 | Sell |
16
-674
| -98% | -$15.1K | ﹤0.01% | 5143 |
|
|
2020
Q3 | $13K | Sell |
690
-2,044
| -75% | -$36.3K | ﹤0.01% | 3987 |
|
|
2020
Q2 | $49K | Buy |
2,734
+1,103
| +68% | +$16.8K | ﹤0.01% | 3057 |
|
|
2020
Q1 | $15K | Buy |
1,631
+1,478
| +966% | +$22K | ﹤0.01% | 1836 |
|
|
2019
Q4 | $3K | Sell |
153
-371
| -71% | -$4.96K | ﹤0.01% | 2886 |
|
|
2019
Q3 | $5K | Buy |
524
+394
| +303% | +$5.3K | ﹤0.01% | 3293 |
|
|
2019
Q2 | $2K | Sell |
130
-5,354
| -98% | -$95.6K | ﹤0.01% | 3244 |
|
|
2019
Q1 | $100K | Buy |
5,484
+3,539
| +182% | +$62.7K | 0.01% | 1429 |
|
|
2018
Q4 | $32K | Sell |
1,945
-1,108
| -36% | -$25.7K | ﹤0.01% | 1591 |
|
|
2018
Q3 | $86K | Buy |
3,053
+2,879
| +1,655% | +$82.7K | 0.01% | 1438 |
|
|
2018
Q2 | $5K | Sell |
174
-581
| -77% | -$17.3K | ﹤0.01% | 3054 |
|
|
2018
Q1 | $24K | Sell |
755
-821
| -52% | -$25.9K | ﹤0.01% | 2071 |
|
|
2017
Q4 | $46K | Buy |
+1,576
| New | +$42.9K | 0.01% | 1387 |
|
|
2016
Q4 | – | Sell |
-200
| Closed | -$5K | – | 3864 |
|
|
2016
Q3 | $5K | Sell |
200
-100
| -33% | -$2.61K | ﹤0.01% | 2524 |
|
|
2016
Q2 | $8K | Buy |
300
+285
| +1,900% | +$8.36K | ﹤0.01% | 3001 |
|
|
2016
Q1 | $0 | Sell |
15
-85
| -85% | -$2.05K | ﹤0.01% | 4198 |
|
|
2015
Q4 | $3K | Sell |
100
-569
| -85% | -$17.3K | ﹤0.01% | 3402 |
|
|
2015
Q3 | $18K | Sell |
669
-499
| -43% | -$16.7K | ﹤0.01% | 1814 |
|
|
2015
Q2 | $42K | Buy |
1,168
+792
| +211% | +$27.8K | ﹤0.01% | 1501 |
|
|
2015
Q1 | $13K | Buy |
+376
| New | +$13.6K | ﹤0.01% | 2577 |
|
Other funds holding CLLS
BGI
LFCM
NAMI
Tower Research Capital (TRC)'s CLLS Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Cellectis (CLLS) stake by 59% in Q1 2026, buying an estimated $2.54K and bringing the position to 1,797 shares worth $5.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4100.
Tower Research Capital (TRC) first reported a position in CLLS in Q1 2015 and has held it in 32 quarters since. The position peaked at $176K in Q1 2021. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.
- Tower Research Capital (TRC) held 1,797 shares of Cellectis worth $5.7K as of Q1 2026.
- Tower Research Capital (TRC) bought 664 Cellectis shares in Q1 2026, an estimated $2.54K.
- Cellectis made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4100 holding.
- Tower Research Capital (TRC) first reported a position in Cellectis in Q1 2015 and has held it in 32 quarters since.
- Tower Research Capital (TRC)'s Cellectis position peaked at $176K in Q1 2021.
- 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.